Search Results
Your search for ,kEY matches 7151 pages
Showing 851 - 900AACR 2025: Trends in Breast Cancer Incidence for Women Between the Ages of 20 and 49
Breast cancer deaths among women between the ages of 20 and 49 declined significantly across all breast cancer subtypes and racial/ethnic groups from 2010 to 2020, with marked declines starting after 2016, according to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER)...
AACR 2025: Survival Outcomes May Improve When Treatment Is Guided by Using Both Tissue and Liquid Biopsies
Although next-generation sequencing to assist decision-making for genomics-driven therapy in patients with advanced solid tumors has traditionally been conducted using tissue biopsy samples, recent data support the use of plasma-based circulating tumor DNA (ctDNA) for the genomic profiling of solid ...
AACR 2025: Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including...
AACR 2025: Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer
Interim results from the VICTORI study showed that an ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay was effective in detecting signs of cancer recurrence prior to imaging and provided prognostic value within 1 month after surgery in patients with colorectal cancer. The...
Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Choong et al found that omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early-stage breast cancer was not associated with improved survival outcomes. The study used National Cancer...
FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer
The U.S. Food and Drug Administration (FDA) has approved the humanized IgG1 monoclonal anti–PD-1 antibody penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC). The FDA also...
WHI Funding Future Unclear
Women’s Health Initiative (WHI) investigators were informed on April 21 that the Department of Health and Human Services (HHS) will terminate WHI Regional Center (RC) contracts at the end of the current fiscal year (September 2025). The WHI Clinical Coordinating Center (CCC) will continue...
Managing Dermatologic Reactions to Combination Therapy for Patients With EGFR-Mutated NSCLC
Nicolas Girard, MD, a thoracic oncologist at the Institut Curie, Paris, presented the results of an interim analysis of the open-label phase II COCOON study, at the European Lung Cancer Congress (ELCC) 2025.1 A readily available preventive regimen (the COCOON regimen) reduced moderate-to-severe...
Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer
Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025. The updated results from the phase III LAURA trial were presented by ...
Is This the End of Cancer Research as We Know It?
Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencing. On February 7, 2025, the chainsaw made its way to facilities and administrative (F&A)...
Polygenic Risk Score for Prostate Cancer Screening
In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Study Details In...
Addition of Daratumumab to Treatment Regimen in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The primary...
Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma
In a Dutch trial (UPGRADE-RT) reported in the Journal of Clinical Oncology, van den Bosch et al found that definitive radiotherapy with reduced-dose elective neck irradiation was safe and effective compared with standard-dose elective neck irradiation in patients with head and neck squamous cell...
Extended Follow-up of Belzutifan Treatment for von Hippel–Lindau Disease–Associated Renal Cell Carcinoma
In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al found that use of the hypoxia-inducible factor-2α inhibitor belzutifan was associated with maintained benefit in patients with von Hippel–Lindau disease–associated renal cell carcinoma. The...
Medicare Claim Denials for Cancer-Related NGS Testing Show Uncertainty of Coverage
More than 20% of cancer-related claims for next-generation sequencing (NGS) from Medicare beneficiaries were denied between 2016 and 2021. Findings from a cohort study published in JAMA Network Open suggested that there is continued uncertainty about the boundaries of coverage for NGS, even with...
Detecting Invasive Nodules Could Be Key to Preventing Unnecessary Pancreatic Cancer Surgery
Some pancreatic cysts may be benign, whereas others have the potential to develop into pancreatic cancer. A recent Japanese study followed 257 patients for an average of 5 years and evaluated the presence or absence of invasive nodules in pancreatic cysts and whether these cysts are benign or...
Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 CAR T Cells in Relapsed/Refractory Mantle Cell Lymphoma
In a single-center phase I/II study reported in the Journal of Clinical Oncology, Shah et al found that adaptive manufactured lentiviral anti-CD20/anti-CD19 (LV20.19) chimeric antigen receptor (CAR) T-cell treatment was highly active in relapsed or refractory mantle cell lymphoma. Study Details In...
CAP Issues New and Updated Cancer Protocols
New protocols for endocrine tumors and updated existing protocols for breast cancer diagnoses are now available from the College of American Pathologists (CAP). These and other updates to protocols reflect the latest scientific advancements, ensuring that pathology reports provide oncologists with...
Activity of ROS1 TKI in NSCLC
In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic ...
How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?
A recent study published by Hooda et al in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has significantly improved access to timely treatment and high-volume hospitals for patients with early-stage non–small cell lung cancer (NSCLC). These findings...
Advanced Esophageal Cancer: NOTCH1 Mutation and Efficacy of Tislelizumab
In an analysis from the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Lu et al found that the presence of NOTCH1 mutation was associated with improved overall survival in patients receiving second-line tislelizumab vs investigator’s choice of chemotherapy for advanced...
Germline Variants May Impact Unique Nature of a Patient’s Cancer, Study Shows
Research into germline genetic variants has identified ways that an individual’s genetic makeup can shape the biology of their cancer. The report, published in Cell, shows how these findings could potentially be applied to future treatment strategies to make cancer treatment more personalized. A...
Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
In the French phase II PANACHE01-PRODIGE48 trial, researchers found that neoadjuvant chemotherapy with mFOLFIRINOX (modified leucovorin, fluorouracil, irinotecan, and oxaliplatin) was feasible and active in patients with resectable pancreatic adenocarcinoma. Schwarz et al published these findings...
ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma
Investigators have identified a key component inhibiting responses to lenalidomide in patients with multiple myeloma, according to the results of a study recently published in Blood. They identified adenosine deaminase acting on RNA1 (ADAR1) as a novel driver of acquired resistance to lenalidomide...
Pediatric ALL or Lymphoblastic Lymphoma: Reduced Induction Dexamethasone and High-Dose Methotrexate
In a UK phase III trial (UKALL 2011) reported in the Journal of Clinical Oncology, Kirkwood et al found that a shorter duration of induction dexamethasone did not reduce steroid-related toxicity and that high-dose methotrexate (HDM) did not reduce central nervous system (CNS) relapse among patients ...
Ideal Apixaban Dose for Cancer-Associated VTE
In the API-CAT trial—results of which were reported in The New England Journal of Medicine—Mahé et al found that use of reduced-dose apixaban was noninferior to full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer. Study Details In the double-blind...
Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al reported activity with the antibody-drug conjugate (ADC) FOR46 in patients with metastatic castration-resistant prostate cancer. As stated by the investigators, “FOR46, a fully human antibody conjugated to monomethyl...
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral ...
Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer
In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality. Study Details In the multicenter study, eligible...
Rescue Therapy for Newly Diagnosed High-Grade Osteosarcoma
In a Japanese trial (JCOG0905) reported in the Journal of Clinical Oncology, Hiraga et al found no disease-free survival benefit with the addition of a higher dose of ifosfamide to methotrexate, doxorubicin, and cisplatin (MAP) in patients with newly diagnosed high-grade osteosarcoma with poor...
Talazoparib Plus Enzalutamide in Advanced Prostate Cancer: Patient-Reported Outcomes
In an analysis from the phase III TALAPRO-2 trial reported in The Lancet Oncology, Matsubara et al found that first-line talazoparib plus enzalutamide was associated with prolonged time to definitive deterioration in global health status/quality of life (GHS/QOL) vs placebo plus enzalutamide in...
Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer
In an analysis from the phase III MIRASOL trial reported in The Lancet Oncology, Van Gorp et al found no significant difference in quality of life between patients receiving mirvetuximab soravtansine vs chemotherapy for folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer. In...
Patterns of ICI Use and Survival Outcomes in Metastatic Colorectal Cancer
In a U.S. population–based cohort study reported in JAMA Network Open, Bari et al identified patterns of immune checkpoint inhibitor (ICI) use and survival outcomes among patients with metastatic colorectal cancer seen in routine clinical practice. The investigators stated: “…ICIs have been...
Radiation Therapy: Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior...
Comparing Biopsy Techniques for Prostate Cancer Detection
In a U.K. trial (TRANSLATE) reported in The Lancet Oncology, Bryant et al found that local anesthetic transperineal (LATP) prostate biopsy detected more Gleason Grade Group (GGG) ≥ 2 prostate cancer compared with transrectal ultrasound (TRUS)-guided biopsy in previously biopsy-naive individuals who ...
Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in...
Smoking Status of the U.S. Cancer Population
In a study reported as a research letter in JAMA Oncology, Caturegli et al attempted to identify smoking status of patients diagnosed with cancer in the United States in 2023. Study Details In the cross-sectional study, the smoking status of patients diagnosed with cancer in 2023 was collected by...
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood. Background Although there are several therapies available to...
Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines
In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelines vs the prior guidelines. In 2021, the USPSTF updated lung cancer screening guidelines by...
Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper-Tract Urothelial Carcinoma
In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper tract urothelial carcinoma. Study Details In this multicenter open-label trial, 45...
Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer
The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP...
Accelerated Onset of Aging-Related Diseases in Childhood Cancer Survivors?
In a study reported in JAMA Oncology, Yeh et al found evidence of accelerated aging in survivors of childhood cancers through the observed increased risk and early onset of age-related diseases. Study Details The study focused on data from the Childhood Cancer Survivor Study and national databases...
Low-Dose CT Screening for Lung Cancer in a High-Risk Population
In a UK prospective longitudinal cohort study (SUMMIT) reported in The Lancet Oncology, Bhamani et al found that large-scale, low-dose computed tomography (CT) screening for lung cancer is effective and “can be delivered efficiently” in a diverse high-risk population. As stated by the...
Presymptomatic Awareness of BRCA1/BRCA2 Status and Outcomes in Ovarian Cancer
In an Israeli retrospective cohort study reported as a research letter in JAMA Network Open, Armon et al found that presymptomatic awareness of BRCA1/BRCA2 pathogenic variant carrier status was associated with better outcomes in several measures in women with ovarian cancer. Study Details The...
Active Surveillance vs Standard Surgery After Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
In a Dutch noninferiority phase III trial (SANO) reported in The Lancet Oncology, van der Wilk et al found that active surveillance was noninferior to standard surgery in terms of 2-year overall survival among patients with esophageal cancer who had a clinical complete response after neoadjuvant...
Neoadjuvant Nivolumab Plus Chemotherapy and Response-Stratified CRT in HPV-Negative Head and Neck Cancer
In a single-center phase II trial (DEPEND) reported in JAMA Oncology, Rosenberg et al found that the combination of neoadjuvant nivolumab and chemotherapy followed by response-stratified chemoradiation (CRT) was active in human papillomavirus (HPV)-negative stage IVa/b head and neck squamous cell...
Health-Related QOL With Belzutifan vs Everolimus in Advanced Renal Cell Carcinoma
In a health-related quality-of-life (QOL) analysis reported in The Lancet Oncology, Powles et al found that belzutifan had better QOL on patient-reported outcomes vs everolimus in patients with advanced renal cell carcinoma in the phase III LITESPARK-005 trial. Study Details Belzutifan is approved...
Early-Stage NSCLC: Geographic Access to Cancer Care and Outcomes
In a study reported in JAMA Network Open, Shrestha et al found that receipt of recommended care and treatment outcomes were associated with geographic access to care in U.S. patients with early-stage non–small cell lung cancer (NSCLC). Study Details The study involved data from the Surveillance,...
Age, ET Persistence, and Disease-Free Survival in HR-Positive Early Breast Cancer
In a French study reported in the Journal of Clinical Oncology, Dumas et al found that improved endocrine therapy (ET) persistence among young patients with hormone receptor (HR)-positive early breast cancer would likely lead to improved disease-free survival. Study Details The study used data from ...
Interventions to Improve Uptake of FIT Colorectal Cancer Screening in Scotland
In a Scottish study (TEMPO) reported in The Lancet, Robb et al found that a behavioral intervention adding a deadline for fecal immunochemical testing (FIT) return in the invitation letter to FIT colorectal cancer screening resulted in superior uptake of testing. Study Details In the trial, 40,000...
